We are live on ! Find out more
KCM

Kynam Capital Management Portfolio holdings

AUM $1.81B
1-Year Est. Return 192.15%
This Fund
S&P 500
This Quarter Est. Return
+20.12%
1 Year Est. Return
+192.15%
3 Year Est. Return
+320.12%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$475M
AUM Growth
+$83M
Cap. Flow
-$17.8M
Cap. Flow %
-3.74%
Top 10 Hldgs %
73.44%
Holding
42
New
8
Increased
11
Reduced
17
Closed
5

Top Buys

Rank Stock Value
1
NTRA icon
Natera
NTRA
+$37.1M
2
UTHR icon
United Therapeutics
UTHR
+$33.8M
3
SNY icon
Sanofi
SNY
+$26.7M
4
GSK icon
GSK
GSK
+$19M
5
CLDX icon
Celldex Therapeutics
CLDX
+$14.3M

Top Sells

Rank Stock Value
1
GBT
Global Blood Therapeutics, Inc.
GBT
+$114M
2
GOSS icon
Gossamer Bio
GOSS
+$24.4M
3
TVTX icon
Travere Therapeutics
TVTX
+$21.1M
4
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$6.45M
5
SNDX icon
Syndax Pharmaceuticals
SNDX
+$5.37M

Sector Composition

Rank Sector Weight
1 Healthcare 99.73%
2 Miscellaneous 0.27%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NTRA icon
1
Natera
NTRA
$47.3B
$88.4M 18.64%
2,018,360
+779,313
+63% +$37.1M
SNDX icon
2
Syndax Pharmaceuticals
SNDX
$1.84B
$54.6M 11.51%
2,272,915
-239,325
-10% -$5.37M
CLDX icon
3
Celldex Therapeutics
CLDX
$3.12B
$45M 9.48%
1,600,127
+467,868
+41% +$14.3M
VERA icon
4
Vera Therapeutics
VERA
$2.59B
$32.7M 6.9%
1,536,181
+13,469
+0.9% +$252K
UTHR icon
5
United Therapeutics
UTHR
$20.9B
$31.6M 6.66%
+151,009
New +$33.8M
SNY icon
6
Sanofi
SNY
$106B
$22.8M 4.81%
+600,000
New +$26.7M
VRDN icon
7
Viridian Therapeutics
VRDN
$2.6B
$20.5M 4.32%
1,000,000
+409,857
+69% +$7.37M
BIIB icon
8
Biogen
BIIB
$32.6B
$20M 4.22%
75,000
-3,951
-5% -$839K
PCVX icon
9
Vaxcyte
PCVX
$9.1B
$16.8M 3.53%
698,638
-25,143
-3% -$637K
BNR
10
Burning Rock Biotech
BNR
$126M
$16M 3.38%
670,386
+240,386
+56% +$7.76M
GSK icon
11
GSK
GSK
$100B
$14.7M 3.1%
+500,000
New +$19M
COGT icon
12
Cogent Biosciences
COGT
$6.03B
$14.7M 3.1%
985,155
-14,845
-1% -$203K
CNCE
13
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$11.2M 2.36%
1,673,041
+673,041
+67% +$4.08M
TVTX icon
14
Travere Therapeutics
TVTX
$6.15B
$10.3M 2.16%
416,729
-818,422
-66% -$21.1M
LQDA icon
15
Liquidia Corp
LQDA
$6.15B
$9.21M 1.94%
1,692,402
+191,684
+13% +$1.08M
GBT
16
DELISTED
Global Blood Therapeutics, Inc.
GBT
$8.94M 1.88%
131,220
-2,068,780
-94% -$114M
AMRN
17
Amarin Corp
AMRN
$288M
$7.33M 1.54%
336,007
+135,512
+68% +$3.63M
FOLD
18
DELISTED
Amicus Therapeutics
FOLD
$7.07M 1.49%
676,849
-223,151
-25% -$2.49M
BCRX icon
19
BioCryst Pharmaceuticals
BCRX
$2.55B
$5.48M 1.16%
435,117
-501,446
-54% -$6.45M
WVE icon
20
Wave Life Sciences
WVE
$958M
$5.04M 1.06%
1,397,479
-299,256
-18% -$991K
MCRB icon
21
Seres Therapeutics
MCRB
$57.5M
$4.96M 1.05%
38,641
+25,709
+199% +$2.63M
AKUS
22
DELISTED
Akouos Inc
AKUS
$4.86M 1.02%
718,394
+334,610
+87% +$1.25M
GOSS icon
23
Gossamer Bio
GOSS
$85.7M
$4.63M 0.98%
386,349
-1,964,099
-84% -$24.4M
PTGX icon
24
Protagonist Therapeutics
PTGX
$9.43B
$4.38M 0.92%
+519,212
New +$4.91M
OLMA icon
25
Olema Pharmaceuticals
OLMA
$941M
$3.86M 0.81%
1,399,633
+1,150,404
+462% +$4.88M
1
2

Similar funds

AF
Aquamarine Financial George Town $1.81B AUM 38.21% 1-Year Est. Return
RP
Regal Partners Sydney, NSW, Australia $1.81B AUM 52.11% 1-Year Est. Return
LPT
Legacy Private Trust Neenah, Wisconsin $1.81B AUM 19.87% 1-Year Est. Return
SFG
Sage Financial Group W. Conshohocken, Pennsylvania $1.81B AUM 22.3% 1-Year Est. Return
GA
Greenspring Advisors Towson, Maryland $1.8B AUM 22.29% 1-Year Est. Return
CCS
Concentric Capital Strategies Stamford, Connecticut $1.8B AUM 51.77% 1-Year Est. Return
PPW
Parcion Private Wealth Bellevue, Washington $1.8B AUM 30.57% 1-Year Est. Return
OPCM
Osborne Partners Capital Management San Francisco, California $1.8B AUM 22.23% 1-Year Est. Return

Kynam Capital Management's Q3 2022 Portfolio in Review

As of Q3 2022, Kynam Capital Management held 42 positions worth $475M, up 21% from $392M the previous quarter. Its ten largest holdings account for 73% of the portfolio.

Kynam Capital Management withdrew a net $17.8M in Q3 2022, closing 5 positions and reducing 17 holdings. Its most notable exit was Merus, an estimated $2.35M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier, followed by Miscellaneous.

Against the trend, Kynam Capital Management opened a new position in United Therapeutics worth $31.6M.

  • Kynam Capital Management's largest Q3 2022 buy was United Therapeutics: 151,009 shares worth $31.6M.
  • Kynam Capital Management added most to Natera in Q3 2022, an estimated $37.1M increase.
  • Kynam Capital Management's biggest Q3 2022 reduction was Global Blood Therapeutics, Inc., cutting an estimated $114M.
  • Kynam Capital Management fully exited Merus in Q3 2022, selling an estimated $2.35M.
  • Kynam Capital Management's ten largest holdings make up 73% of its $475M portfolio in Q3 2022.
  • Kynam Capital Management opened 8 new positions and closed 5 in Q3 2022.
  • Kynam Capital Management's portfolio value rose 21% quarter-over-quarter to $475M.

Based on Kynam Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.